Accéder au contenu
Merck
Toutes les photos(1)

Documents

B-006

Supelco

Butalbital solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonyme(s) :

5-Allyl-5-isobutylbarbituric acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C11H16N2O3
Numéro CAS:
77-26-9
Poids moléculaire :
224.26
Numéro MDL:
MFCD00056089
Code UNSPSC :
41116107
ID de substance PubChem :
329773093
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

InChI

1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)

Clé InChI

UZVHFVZFNXBMQJ-UHFFFAOYSA-N

Informations sur le gène

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Butalbital is a barbiturate often combined with other medications such as acetaminophen or aspirin for the treatment of pain or codeine for headaches. Trade names of several butalbital combinations include Axocet®, Bucet, and Bupap® with acetaminophen and Axotal with aspirin. This certified reference solution is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or urine drug testing.

Application


  • Butalbital API for Research: Investigates Butalbital as an active pharmaceutical ingredient (API), focusing on its properties and applications in synthesizing complex pharmaceutical formulations, essential for developing new barbiturate-based treatments (Yang et al., 2022).

  • Butalbital Compound Synthesis: Explores the synthesis of Butalbital and its derivatives, underlining its critical role in the development of CNS depressants and its pharmacological potential in neurobiological research (Marmura et al., 2015).

  • Barbiturate Biochemical Research: Focuses on Butalbital′s effects on human platelet aggregation, offering insights into its mechanism of action within the cardiovascular system, which is vital for tailoring barbiturate-based therapies (Sato et al., 2003).

  • Butalbital Pharmacological Studies: Discusses the pharmacological profiling of Butalbital, emphasizing its utility in managing acute pain and headaches, thereby supporting its continued use in clinical settings for migraine and tension headache relief (Mazer-Amirshahi et al., 2014).

  • CNS Depressant Research Chemical: Analyzes Butalbital′s role as a central nervous system depressant, assessing its effectiveness and safety profile, which is crucial for its application in chronic pain management and treatment of cluster headaches (Cutrer et al., 1999).



Informations légales

Axocet is a registered trademark of Fougera Pharmaceuticals Inc.
Bupap is a registered trademark of ECR Pharmaceuticals Co., Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Seymour Solomon
Current pain and headache reports, 6(2), 147-150 (2002-03-02)
Butalbital compounds are of proven efficacy in the treatment of tension headache. Decades of experience have established their value in the treatment of other mild-to-moderate headaches. Untold numbers of people rely on these medications as their drug of choice or
Richard G Wenzel et al.
Pharmacotherapy, 22(8), 1029-1035 (2002-08-14)
To evaluate the role of butalbital-containing products in the management of migraine. Qualitative systematic search using MEDLINE (January 1966-November 2001), review of the United States Headache Consortium's evidence-based guidelines for migraine treatment, and review of other pertinent literature. Over 28
W T Chang et al.
Journal of analytical toxicology, 25(8), 659-669 (2002-01-05)
As a part of our study on the use of isotopic analogues as the internal standard (IS) for the quantitation of drug analytes, this article reports on the performance characteristics of 2H5-butalbital and 13C4-butalbital with particular focus on (1) determining
William B Young et al.
Current pain and headache reports, 6(2), 151-155 (2002-03-02)
In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. These agents can cause physical and psychological dependency, and dangerous withdrawal syndromes. Butalbital-containing analgesics have already been banned in several European countries. They are proven effective in tension-type
Karla A Moore et al.
Forensic science international, 134(2-3), 120-122 (2003-07-10)
Zaleplon ("Sonata") is a pyrazolopyrimidine derivative approved for use in the United States for the treatment of insomnia. To date, there has been little data in the toxicological literature where zaleplon has been implicated as causing a fatal intoxication, either
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique